The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
Abstract: to learn the role of
docetaxel in non-castrate resistant prostate cancer patient. Methods:
literature search was conducted to find relevant study comparing the
combination of docetaxel and androgen deprivation therapy (ADT) to ADT alone in
non-castrate resistant prostate cancer using PubMed, Cohrane Library, Proquest,
EBSCO, and Scopus database. Quality assessment of studies was done using Bond
University Rapid Critical Appraisal of a Systematic Review. Results: we found
494 studies from literature search, but only two studies were included in final
selection. Based on validity assessment, we chose one study to be discussed
further. This study showed that combination of docetaxel and ADT is better than
ADT alone in regards of overall survival (HR 0.64; 95% CI 0.55, 0.75;
p<0.0001; NNT=3), biochemical progression free survival (HR 0.63; 95% CI
0.57, 0.69; p<0.0001; NNT=2) and clinical progression free survival (HR
0.73; 95% CI 0.64, 0.84; p<0.0001; NNT=2). Benefit of docetaxel and ADT
combination was especially seen in high volume disease (HR 0.67; 95% CI 0.54,
0.83; p=0.0003; NNT=3). Conclusion: addition of docetaxel into ADT has
beneficial effects in terms of overall survival and progression free survival
in patients with non-castrate resistant metastatic prostate cancer.
Keywords: Docetaxel; androgen
deprivation therapy; evidence-based case report; metastatic prostate cancer;
overall survival
Author: Fakhri Rahman, Harrina
Erlianti Rahardjo, Stefanus Cahyo Ariwicaksono, Hafizar Hafizar, Muhammad
Gozali Arif Sembiring, Rendy Andika, Richman Patandung, Septiani Hidianingsih,
Stevano Lucianto Hotasi
Journal Code: jpkedokterangg170330
